Syndax halts Niktimvo trial for idiopathic pulmonary fibrosis after mid-stage failure
Syndax announced it will stop testing Niktimvo (axatilimab) in idiopathic pulmonary fibrosis after the Phase 2 MAXPIRe trial failed to meet its primary endpoint.
The study enrolled 145 patients and the drug did not significantly slow the decline in forced vital capacity over 26 weeks, leading to discontinuation of the IPF program.
Despite the setback, Syndax will continue pursuing label expansion of Niktimvo for chronic graft‑versus‑host disease, the indication for which it received approval in 2024.
The news sent the company's shares down about 10% in pre‑market trading, reflecting investor disappointment.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Syndax ends fibrosis program for Niktimvo after mid-stage disappointment”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that